文献速递冠心病外科

他汀强度对冠状动脉旁路移植术后长期结局的影响

Effects of Statin Intensity on Long-term Outcomes After Coronary Artery Bypass Grafting.
PubMed 文献 · Ann Thorac Surg · 2021-09-21

本研究纳入6531例CABG患者,按他汀强度分4组,主要终点为5年MACCE。至少中等强度他汀较无/低强度显著降低5年MACCE风险(HR 0.694),较高中等强度和高强度均优于较低中等强度,且在ACS亚组中交互作用显著。

要点

  • 至少中等强度他汀与CABG术后5年MACCE风险降低相关。
  • 较高中等强度(阿托伐他汀20mg等效)和高强度他汀均优于较低中等强度。
  • ACS患者从较高强度他汀获益更显著,稳定缺血性心脏病患者无此交互。

核心结论

  • 至少中等强度他汀与CABG术后5年MACCE风险降低显著相关。
  • 较高中等强度或高强度他汀优于较低中等强度他汀,尤其在ACS患者中。

研究设计与样本

  • 回顾性队列研究,纳入6531例CABG患者,按他汀强度分4组。
  • 主要终点为5年MACCE,采用多因素Cox和逆概率加权调整基线差异。

关键数值与推荐

  • 他汀强度分组:无/低强度(阿托伐他汀<10mg)、较低中等强度(阿托伐他汀10mg等效)、较高中等强度(阿托伐他汀20mg等效)、高强度(阿托伐他汀≥40mg等效)。

临床怎么用

  • CABG术后应考虑至少使用中等强度他汀,ACS患者可优先选择较高中等或高强度他汀以降低5年MACCE风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The current study sought to investigate the association between statin intensity and long-term clinical outcomes according to initial clinical presentation after coronary artery bypass grafting (CABG). METHODS: The 6531 patients who underwent CABG included in this study were classified into 4 groups according to statin intensity: 731 in the no or low statin group (atorvastatin <10 mg), 2310 in the lower-moderate group (atorvastatin 10-mg equivalent), 2404 in the higher-moderate group (atorvastatin 20-mg equivalent), and 1086 in the high-intensity group (atorvastatin ≥ 40-mg equivalent). The primary endpoint was major adverse cardiac and cerebrovascular events (MACCE) at 5 years. Multivariate Cox and inverse probability weighting methods were performed to adjust for baseline differences. RESULTS: At least moderate-intensity statin use was associated with significantly lower risk of 5-year MACCE compared with no or low-intensity statin use (hazard ratio [HR], 0.694; 95% confidence interval [CI], 0.493-0.977; P = .036). Among patients who were taking at least a moderate-intensity statin, both higher-moderate intensity (HR, 0.622; 95% CI, 0.479-0.807; P < .001) and high-intensity statin (HR, 0.613; 95% CI, 0.421-0.894; P = .011) groups showed significantly lower risks of MACCE than the lower-moderate intensity statin group at 5 years after CABG. There was no significant difference in the risk of MACCE between higher-moderate intensity and high-intensity statin groups (HR, 0.987; 95% CI, 0.661-1.475; P = .950). Multivariable Cox and inverse probability weighting methods yielded similar results. In a subgroup analysis compared with the use of a lower-moderate intensity statin, the use of a higher-moderate or high-intensity statin (equivalent dose with atorvastatin ≥20 mg) was associated with a significantly lower risk of MACCE among CABG patients who presented with acute coronary syndrome but not in those who presented with stable ischemic heart disease (interaction P = .001). CONCLUSIONS: The use of a lower-moderate intensity statin (atorvastatin 10-mg equivalent) was associated with relatively poorer long-term clinical outcomes than the use of higher-moderate or high-intensity statin, especially in acute coronary syndrome patients after CABG.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Jang YH, Choi KH, Song YB, et al. Effects of Statin Intensity on Long-term Outcomes After Coronary Artery Bypass Grafting. Ann Thorac Surg. 2021. PMID: 34555373. doi:10.1016/j.athoracsur.2021.08.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。